Antibody-drug conjugates
Oct 1, 2018 ·
1m 1s
![Antibody-drug conjugates](https://d3wo5wojvuv7l.cloudfront.net/t_square_limited_480/images.spreaker.com/cloudinary/s--9yvHUvpc--/w_1000,h_800,c_fit,l_text:Lato_157_bold:Antibody%20drug%20conjugate/images.spreaker.com/default/show-1400x1400-20190801.jpg)
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
Antibody-drug conjugates selectively and continuously deliver cytotoxic drugs to tumors. Its three main components are antibodies, cytotoxic agents and linkers. Many monoclonal antibodies are standard therapies for solid tumors and...
show more
Antibody-drug conjugates selectively and continuously deliver cytotoxic drugs to tumors. Its three main components are antibodies, cytotoxic agents and linkers. Many monoclonal antibodies are standard therapies for solid tumors and hematological cancers, while primary chemotherapy drugs have limited therapeutic effects on cancer due to their non-specific toxicity. The discovery of ADC fills the gap between the two. Mylotarg is the first FDA approved ADC for acute myeloid leukemia. Adcetris is a conjugate of the CD30 antibody and monomethyl auristatin E and is approved for the treatment of lymphoma. Kadcyla has been commercialized for HER-2 positive metastatic breast cancer. The challenges faced by ADCs include antibody immunogenicity, antigen expression, premature drug release, etc. Progress in bioengineering has improved its safety and efficacy.
https://www.creative-biolabs.com/adc/services.htm
show less
https://www.creative-biolabs.com/adc/services.htm
Information
Author | Bella Smith |
Organization | Bella Smith |
Website | - |
Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company